Sanofi’s Paul Hud­son pays $357M to buy a biotech part­ner, adding an NK strat­e­gy in the lat­est move to beef up can­cer R&D

A year af­ter Am­s­ter­dam-based Kiadis un­der­went a wrench­ing re­or­ga­ni­za­tion af­ter its lead drug went pffffffft at the EMA, bat­ter­ing the share price and butcher­ing the mar­ket cap, Sanofi’s deal hun­gry CEO is swoop­ing in for the low-cost buy­out.

Paul Hud­son has agreed to buy the com­pa­ny for €308 mil­lion ($357 mil­lion), which is a whole lot more than the mi­nus­cule mar­ket cap $KDS left be­hind af­ter the stock flat­lined last No­vem­ber. The stock closed Fri­day at €1.46, less than a third of the €5.45-per-share Sanofi is pay­ing for the 23-year-old play­er, which Sanofi part­nered with last sum­mer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER